Table 3.

Multiple Linear Regression Models for Past 30-Day Follow-up Use of Highest Scoring Drug (HSD^a)^b

Total Sample (n=334)
Measure	Estimate	s.e.	95% CI	P
Intervention Program	-2.21	0.79	-3.76, -0.65	.005
Baseline HSD Use	0.69	0.04	0.61, 0.77	.001
HSD ASSIST Score	0.14	0.07	0.01, 0.28	.037
Interval between baseline and follow-up surveysc	0.68	0.25	0.20, 1.16	.006
General Health Statusd	-0.73	0.40	-1.50, 0.04	.064
Interest in quitting/reducing HSD usee	1.44	0.69	0.09, 2.79	.037

Patients with Baseline Highest Scoring Drug Use 0–4 Days, Past 30 Days (n=154)
Measure	Estimate	s.e.	95% CI	P
Intervention Program	0.08	0.75	-1.39, 1.55	.915
Intervalc	1.29	0.24	0.83, 1.17	.001
Healthd	-1.06	0.37	-1.79, -0.33	.004

Patients with Baseline Highest Scoring Drug Use 5 or More Days, Past 30 Days (n=180)
Measure	Estimate	s.e.	95% CI	P
Intervention Program	-4.01	1.33	-6.63, -1.40	.003
Baseline HSD Use	0.69	0.07	0.56, 0.83	.001
HSD ASSIST Score	0.21	0.12	- 0.02, 0.45	.075
Male	2.94	1.41	0.19, 5.70	.036
Actionf	-0.32	0.18	-0.67, 0.04	.078
TB History	-7.82	4.59	-16.82, 1.17	.088

^aHighest scoring drug in risky range (4–26) on WHO ASSIST

^bAfter multiple imputation of missing predictor values

^cInterval in days between baseline and follow-up surveys

^dGeneral health (1 = Excellent, 5 = Poor)

^eInterest in quitting/reducing HSD use (1 = very interested, 3 = not at all interested)

^fScore on the Action Readiness to change scale